查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495996

全球內分泌檢測市場－2024年至2029年預測

Global Endocrine Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年內分泌檢測市場規模為114.2億美元，預計預測期內複合年成長率為6.35%，2029年達到175.74億美元。

內分泌系統是一組產生荷爾蒙的腺體，有助於調節各種身體功能，包括新陳代謝、性發育、生長和體重。內分泌測試評估荷爾蒙水平並了解內分泌腺的功能。在全球範圍內，所有年齡層的荷爾蒙失衡現像都在加劇，這推動了內分泌檢測市場的發展。

疾病發生率的增加促進了先進診斷技術的發展，進一步增加了對先進檢測方法的需求。儘管這些技術可能很快就會獲得市場關注，但與開發相關的巨大成本可能會阻礙快速商業化並限制市場成長。

由於對內分泌檢測工具的高需求，市場相關人員正在專注於開發新產品。例如，DRG Diagnostics於2018年10月推出了免費的T4 ELISA檢測套組。此 ELISA套件用於直接定量測量人類血清中的遊離甲狀腺激素。

在全球範圍內，糖尿病患者、老年人和肥胖者數量的增加應會推動市場成長。此外，個人健康意識的提高以及政府的支持將增加早期診斷的數量，從而促進內分泌檢測市場的成長。由於甲狀腺機能低下症和甲狀腺功能亢進等疾病，對先進內分泌檢測技術的需求預計也會成長。

市場促進因素：

  • 測量促甲狀腺刺激素(TSH) 的檢測預計將在內分泌檢測市場中成長。

腦下垂體刺激激素 (TSH) 刺激甲狀腺產生甲狀腺素和三碘甲狀腺原氨酸，有助於新陳代謝。 TSH 測試用於測量甲狀腺水平。在過去的十年中，甲狀腺疾病在世界各地有所增加。根據美國甲狀腺協會 (ATA) 估計，2019 年有 2,000 萬美國患有某種形式的甲狀腺疾病。預計超過 12% 的美國公民在一生中的某個階段會患上甲狀腺疾病。

吸菸、飲酒和菸草使用是甲狀腺相關疾病最重要的危險因子。荷蘭格羅寧根大學腎內科和格羅寧根大學醫學中心的研究人員於 2019 年 11 月進行的一項研究表明，每天吸煙與 TSH 水平較低以及 FT4 和 FT3 水平較低有關。

技術趨勢使甲狀腺功能測試更具成本效益，甲狀腺激素測量最近變得越來越重要。因此，TSH 檢測的增加預計將推動內分泌檢測市場的成長。

  • 全球老年人口的增加預計將推動內分泌檢測市場的成長。

除了與老齡化相關的生長激素下降之外，內分泌系統的變化還包括女性閉經、骨質減少、男性雄激素缺乏以及 2 型糖尿病發生率增加。隨著老齡化，內分泌系統會發生一系列影響荷爾蒙水平的變化。這就是為什麼全球老年人口的增加是推動內分泌檢測市場成長的關鍵因素之一。

根據聯合國2019年世界人口展望資料，世界人口將在30年內加倍，從77億增加到97億，同時人口將快速老化。 65 歲及以上人口數量將從 2019 年的十分之一（9%）增加到 2050 年的六分之一（16%）。此外，3,420 萬美國人（略高於十分之一）患有糖尿病。三分之一的美國成年人（約 8,800 萬人）患有糖尿病前期。 （圖片來源：疾病預防控制中心）

市場限制因素：

  • 高技術成本可能會阻礙內分泌檢測市場的成長。

對於內分泌測試製造商來說，研發活動和後續測試商業化的高成本是一個嚴峻的挑戰。因此，監測和診斷個體的荷爾蒙分泌量變得非常昂貴。例如，羅氏公司 2019 會計年度在研發活動上投資約 116 億美元。雅培公司的大部分收益都投資於新產品和技術的研發。結果，最終產品非常昂貴，這增加了診斷技術的成本，並對市場產生負面影響。

預計北美市場將主導內分泌檢測市場。

北美在內分泌檢測市場的主導地位是由先進的醫療基礎設施、技術創新、內分泌疾病的高患病率、提高的認知和篩檢計劃、支持性的法規環境、主要市場參與企業的強大存在以及高醫療支出推動的。美國和加拿大擁有先進的醫療基礎設施，導致先進診斷工具和設備的引進和使用。

糖尿病、甲狀腺疾病、荷爾蒙失調等內分泌疾病的高盛行率是由於久坐的生活方式、不良的飲食習慣和老化等因素造成的。意識和篩檢計劃正在鼓勵定期內分泌檢測，進一步推動需求。

由 FDA 和加拿大衛生署監督的支持性法規環境可促進創新並確保內分泌檢測產品的安全性和有效性。美國的高醫療保健支出使個人和醫療機構能夠投資於先進的診斷服務，包括內分泌檢測，進一步推動市場成長。

主要發展

  • 2023 年 11 月 - 諾和諾德、MEMS 和羅氏合作在馬來西亞推出「改變兒童糖尿病」(CDiC)計劃。此舉措為兒童和年輕人提供免費的血糖監測用品，是糖尿病管理的重要一步。該舉措還有助於改善獲得護理的機會，與今年世界糖尿病日內分泌測試「獲得糖尿病護理」一致。
  • 2022 年 5 月 - 總部位於柏林的 Inne.io 獲得 930 萬歐元資金，用於擴展其荷爾蒙追蹤技術。該Start-Ups旨在解決女性醫療保健資金缺乏以及對個人化和數位化醫療保健的渴望的問題。本輪資金籌措主導。 Inne.io 旨在為各個生命階段的女性提供服務，並解決女性健康方面的交叉差異，特別是老年女性的健康，她們在醫療保健方面經常被忽視。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球內分泌檢測市場：依技術分類

  • 介紹
  • 液相層析法質譜法 (LC-MS)
  • 免疫檢測
  • ELISA
  • 串聯式質譜質譜法
  • 其他

第6章全球內分泌檢測市場：依應用分類

  • 介紹
  • 皮質醇測試
  • 人類絨毛膜促性腺激素分泌（HCG）測試
  • 硫酸去氫表雄酮（DHEAS）測試
  • 甲狀腺刺激素（TSH）測試
  • 催乳素測試
  • 胰島素
  • 其他

第7章全球內分泌檢測市場：依最終用戶分類

  • 介紹
  • 醫院和診所
  • 診斷中心

第8章全球內分泌檢測市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Randox Laboratories Ltd
  • Abbott
  • Agilent Technologies, Inc
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc
  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Siemens Medical Solutions
  • Thermo Fisher Scientific
簡介目錄
Product Code: KSI061611696

The global endocrine testing market was valued at US$11.420 billion in 2022 and is expected to grow at a CAGR of 6.35% over the forecast period to reach a total market size of US$17.574 billion by 2029.

An endocrine system is a set of hormone-producing glands that help regulate different body functions, such as metabolism, sexual development, growth, and weight. Endocrine testing involves assessing hormonal levels to determine how the glands are functioning. Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Increased disease incidence has prompted the development of advanced diagnostic technologies, which further increases the need for sophisticated testing methods. While these technologies are likely to gain some attention in the market shortly, significant costs associated with developing them could hamper their rapid commercialization, thus limiting the market's growth.

Since endocrine testing tools are in high demand, market players are more committed to developing new products. For example, DRG Diagnostics launched free T4 ELISA test kits in October 2018. This ELISA kit is intended to measure free thyroid hormone in human serum directly and quantitatively.

Globally, an increasing number of diabetics, geriatrics, and obese people should promote market growth. In addition, growing health awareness among individuals, along with government support, will increase the number of early diagnoses and thereby contribute to the endocrine testing market growth. The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.

Market Drivers:

  • Tests to measure thyroid-stimulating hormone (TSH) are expected to grow the endocrine testing market.

Pituitary-stimulating hormone (TSH) stimulates the production of thyroxine and triiodothyronine by the thyroid gland, which aids metabolism. The TSH test is used to determine thyroid levels. Over the past decade, thyroid disorders have increased worldwide. According to the American Thyroid Association (ATA), 20 million Americans are estimated to have some form of thyroid disease in 2019. More than 12% of US citizens are expected to suffer from thyroid disease at some point in their lives.

Smoking, alcohol consumption, and tobacco use are the most important risk factors for thyroid-related disorders. In a study conducted in November 2019 by researchers from the Department of Nephrology at the University of Groningen and University Medical Center Groningen, The Netherlands, findings showed that daily cigarette smoking was associated with lower levels of TSH and lower levels of FT4 and FT3.

Technology developments have allowed thyroid function tests to become more cost-effective, and thyroid hormone measurement has recently gained importance. As a result, the rise in TSH testing is expected to boost the global endocrine testing market's growth.

  • The rise in the geriatric population worldwide is anticipated to boost the endocrine testing market growth.

In addition to declines in growth hormones associated with aging, changes in the endocrine system include menopause in women, skeletal mass loss, androgen deficiency in men, and an increased incidence of type 2 diabetes. The endocrine system undergoes a series of changes that affect the hormone levels of people as they age. This is why the rise of the global geriatric population is one of the primary factors driving the endocrine testing market's growth.

According to the United Nations (UN) data on World Population Prospects for 2019, the world's population will double within 30 years, from 7.7 billion to 9.7 billion, and at the same time, the world will age more rapidly. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%). Additionally, 34.2 million Americans (just over one in ten) have diabetes. A third of American adults, approximately 88 million, have prediabetes. (Source: CDC)

Market Restraints:

  • The high cost of technology could hinder the endocrine testing market growth.

For endocrine testing manufacturers, the high cost of research and development activities and subsequent commercialization of tests represent a serious challenge. Thus, monitoring and diagnosing an individual's hormone secretion levels has become extremely expensive. Roche, for instance, invested approximately USD 11.6 billion in research and development activities in the financial year 2019. A significant portion of Abbott Laboratories' revenues are invested in the research and development of novel products and technologies. As a result, the end product is very expensive, which adds to the cost of diagnostic technologies, which impacts the market negatively.

The North American market is predicted to dominate the global endocrine testing market.

North America's dominance in the global endocrine testing market is attributed to its advanced healthcare infrastructure, technological innovation, high prevalence of endocrine disorders, rising awareness and screening programs, supportive regulatory environment, strong presence of key market players, and high healthcare spending. The United States and Canada have advanced healthcare infrastructure, leading to the adoption and utilization of advanced diagnostic tools and devices.

The high prevalence of endocrine disorders, such as diabetes, thyroid disorders, and hormonal imbalances, is driven by factors such as sedentary lifestyles, poor dietary habits, and an aging population. Increased awareness and screening programs encourage individuals to undergo regular endocrine testing, further boosting demand.

The supportive regulatory environment, overseen by the FDA and Health Canada, fosters innovation and ensures the safety and efficacy of endocrine testing products. The United States' high healthcare expenditures enable individuals and healthcare institutions to invest in advanced diagnostic services, including endocrine testing, further fuelling market growth.

Key Developments:

  • November 2023- Novo Nordisk, MEMS, and Roche partnered to launch the Changing Diabetes(R) in Children (CDiC) project in Malaysia, aiming to improve care for children and young adults below 25 with type 1 diabetes. The initiative provide free glucose monitoring supplies to children and young adults, is a significant step in diabetes management. The initiative also contribute to improving access to care, aligning with this year's World Diabetes Day theme of "Access to Diabetes Care." The initiative aims to improve the quality of care for children and young adults with type 1 diabetes.
  • May 2022- Berlin-based Inne.io secured €9.3 million in funding to expand its hormone-tracking tech. The startup aims to address the underfunding of women's healthcare and the desire for personalized and digitalized healthcare. The funding was led by DSM Venturing, Borski Fund, Calm Storm Ventures, and high-profile angels Taavet Hinrikus (Wise), Dr Fiona Pathiraja, and Rolf Schromgens (Trivago). Inne.io aims to offer services to women at all stages of life, addressing the intersectional gap in women's health, particularly older women who are often neglected in healthcare.

Segmentation:

By Technology

  • Liquid Chromatography-Mass Spectrometry (LC-MS)
  • Immunoassay
  • ELISA
  • Tandem Mass Spectrometry
  • Others

By Application

  • Cortisol Test
  • Human Chorionic Gonadotropin (HCG) Test
  • Dehydroepiandrosterone Sulfate (DHEAS) Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Insulin
  • Others

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ENDOCRINE TESTING MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Liquid Chromatography-Mass Spectrometry (LC-MS)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Immunoassay
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. ELISA
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Tandem Mass Spectrometry
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL ENDOCRINE TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cortisol Test
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Human Chorionic Gonadotropin (HCG) Test
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Dehydroepiandrosterone Sulfate (DHEAS) Test
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Thyroid Stimulating Hormone (TSH) Test
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Prolactin Test
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Insulin
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness
  • 6.8. Others
    • 6.8.1. Market Opportunities and Trends
    • 6.8.2. Growth Prospects
    • 6.8.3. Geographic Lucrativeness

7. GLOBAL ENDOCRINE TESTING MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Centres
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL ENDOCRINE TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Randox Laboratories Ltd
  • 10.2. Abbott
  • 10.3. Agilent Technologies, Inc
  • 10.4. bioMerieux SA
  • 10.5. Bio-Rad Laboratories, Inc
  • 10.6. F. Hoffmann-La Roche Ltd
  • 10.7. Beckman Coulter, Inc.
  • 10.8. Siemens Medical Solutions
  • 10.9. Thermo Fisher Scientific